New Therapy For Advance Melanoma Safe and Effective

A new study published in The Lancet has shown the BRAF inhibitor medication dabrafenib is active and safe in patients with advanced melanoma, with positive results in those with brain metastases. Dabrafenib blocks the activity of the mutated BRAF gene, which is found in around half of all cases of metastatic melanoma. In a phase I trial, that dabrafenib treatment elicited responses in 69% and confirmed responses in 50% of 36 patients with the most common form of BRAF-mutated metastatic melanoma.